Chronic myeloid leukemia in blast crisis (BC) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) are associated with extremely poor outcome. Allogeneic transplantation during BC or active leukemia is most often unsuccessful due to high-rates of both treatment-related complications and relapse. Long-term results are significantly better if a second chronic phase or remission can be achieved prior to transplantation. Similarly, DLI given for the treatment of posttransplant relapse is more successful when given during a second remission. In this study we report our results with a previously unreported approach consisting of short-term treatment with imatinib mesylate (formerly, STI571) to induce or maintain remission, followed by allogeneic transplantation or DLI and the impact on transplantation/DLI outcome. Sixteen patients were treated either in preparation for transplantation (n = 12), for DLI (n = 1), or for both (n = 3). Ten had CML in BC; seven myeloid and three lymphoid BC. Six patients had Ph + ALL. The donors were matched unrelated (n = 9), matched siblings (n = 5) or haplo-identical (n = 2). Eleven of 15 patients given imatinib pre-transplant were transplanted in complete hematologic response. Engraftment and GVHD rates were not different from expected. Seven patients had grade II-III hepatic toxicity after transplantation. After a median follow-up of 10 months (range, 3-16 months) six remain alive, two after further therapy. The 1-year survival rate was 25%. Four patients were given imatinib prior to DLI, all had complete response. Two remain in remission >6 months from relapse. In conclusion, treatment with imatinib allows transplantation in a more favorable status or maintaining remission with low toxicity until transplantation is feasible. Pre-transplant imatinib seems safe and not associated with excess post-transplant complications. Imatinib may have substantial activity in combination with DLI. Further study of a larger group of patients is required to assess the impact on long-term outcome and the role of post-transplant imatinib in controlling residual disease.
Introduction
Chronic myeloid leukemia (CML) is initiated by the BCR/ABL fusion gene associated with the Philadelphia chromosome or t(9;22) reciprocal translocation. This fusion gene codes for a tyrosine kinase, which is constitutively active and mediates leukemic transformation. 1, 2 CML inevitably progresses to a terminal phase known as the blast crisis (BC). The development of BC in patients with CML carries extremely poor prognosis. This phase resembles acute leukemia but is highly refractory to treatment. [3] [4] [5] [6] Only 20-30% of patients with myeloid BC respond to induction chemotherapy and the median survival is 3-6 months. [3] [4] CML in lymphoid BC frequently responds better to first-line chemotherapy with remissions achieved in 60-90% of patients. 5, 6 Median survival is longer than in myeloid BC reaching 9-12 months.
The results of allogeneic transplantation during BC are disappointing with a median survival of approximately 6 months after transplantation and less than 10% of recipients achieving long-term disease-free survival. Both high rates of transplantrelated mortality and post-transplant relapse contribute to the dismal outcome. [6] [7] [8] [9] [10] Long-term results are significantly better if a second chronic phase can be restored with front-line therapy prior to transplantation. 6, 9, 10 Up to 20% of adults and 5% of children with acute lymphoblastic leukemia (ALL) harbor the BCR/ABL fusion gene. The prognosis of this leukemia subtype is dismal. Allogeneic transplantation given at first complete remission can improve outcome significantly, 11, 12 however, results remain poor for refractory or relapsing disease. Patients in first remission may relapse rapidly if transplantation is delayed while searching for a donor or for other reasons.
Donor lymphocyte infusion (DLI) emerged as the treatment of choice for CML relapsing post-allogeneic transplantation in cytogenetic or chronic phase. [13] [14] [15] However, DLI has very limited success when given for CML relapsing in BC or for active leukemia.
Imatinib mesylate (formerly, STI571) is a potent, selective BCR/ABL tyrosine kinase inhibitor. 16 Imatinib is given orally and has a safe toxicity profile. Imatinib has substantial activity in CML in chronic phase. 17 Imatinib also has substantial activity with a favorable safety profile as single agent in patients with myeloid BC. In two recently reported large phase II studies, 53-55% of patients with myeloid BC achieved complete hematologic response lasting a median of 10 months. The median survival and 1-year survival rates were approximately 7 months and 30%, respectively. 18, 19 Imatinib was less toxic and produced higher response rate and survival when compared to historical control group treated with chemotherapy. 19 The role of imatinib in lymphoid BC is less established than in myeloid BC. The response rate is 30-70% but the median remission duration is only 2 months. 19, 20 Imatinib is also active in Ph + ALL 21 and in the treatment of posttransplant relapse. [22] [23] [24] [25] [26] [27] The impact of pre-transplant treatment with imatinib on engraftment, toxicity, GVHD, and other post-transplantation parameters is currently unknown. We speculated that achieving disease control in patients with Philadelphia-positive acute leukemias with the use of imatinib, prior to allogeneic transplantation or DLI, even if expected to be short-lived, will improve transplantation or DLI outcome.
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Patients and treatment
Patients were eligible for this study if they had CML in myeloid or lymphoid BC or Ph + ALL. Patients were selected on the basis of having a donor, eligibility and referral to the transplant centers. Imatinib was given for treatment of active leukemia prior to transplantation or DLI or to maintain remissions achieved with chemotherapy until transplantation, if it had to be delayed. Patients could have had any prior therapy including prior transplantation. Patients were required to be free of marked organ dysfunction and to have an ECOG performance score of <2. All patients gave written informed consent and the study was approved by the institutions' review boards.
Imatinib was started at a single daily dose of 400-600 mg at the attending physician's discretion (Table 1 ). Most patients x patients given additional chemotherapy after imatinib failure d Imatinib discontinued less than 1 week from the start of conditioning (i) or 1-2 months before conditioning(ii) f For criteria of response refer to Patients and methods; CR, complete hematologic remission; neg FISH, FISH test on marrow sample showing no BCR/ABL fusion; CP, restoration of chronic phase; cont CR, continuous CR; NR, no response; marrow CR, marrow remission without recovery of peripheral blood counts. g AcGVHD, acute graft-versus-host disease; ChGVHD, chronic GVHD; VOD, veno-occlusive disease of the liver, *also given imatinib for post-BMT relapse (refer to Table 2 ).
Leukemia were treated within Novartis sponsored phase II studies. Imatinib was given until achievement of hematological response and hematopoietic transplantation was administered as soon as possible afterwards. Imatinib was stopped in responding patients within a few days of starting conditioning for transplantation and not resumed afterwards until relapse. Imatinib was discontinued after 28 days of treatment if there was no response and further therapy was allowed before transplant.
The conditioning regimen for patients with lymphoid BC/ALL included total body irradiation (TBI) and high-dose cyclophosphamide (Table 1 , patients 5, 6, 7) with the addition of etoposide in some patients (Table 1 , patients 4, 8) . Patients with myeloid-BC were conditioned with busulfan cyclophosphamide and etoposide (Table 1 , patients 9, 10, 12, 13, 14). All recipients of unrelated donor grafts were also given ATG. Three patients were given reduced intensity regimen consisting of fludarabine, reduced dose of busulfan and ATG (Table 1 , patients 1, 2, 11) due to prior transplant procedure (n = 2) or poor performance (n = 1). The regimen for haploidentical transplant (Table 1 , patients 3, 11) included TBI, thiotepa, fludarabine and ATG. Allografts were peripheral blood stem cells in 13 transplants and bone marrow grafts in three transplants.
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GVHD prophylaxis consisted of cyclosporine and shortcourse methotrexate. Grafts from haplo-identical donors were T cell depleted and no additional post-transplant GVHD prophylaxis was given. Standard prophylactic antibiotics for prevention of bacterial, fungal, viral, and pneumocystis infection were given by institutional protocols.
Patients relapsing after prior transplantation were eligible for DLI from the original related or unrelated donor after a second course of imatinib. Imatinib was continued after DLI as maintenance treatment until relapse.
Evaluation of response
BC or acute leukemia was defined when more than 30% blasts were present in the bone marrow or peripheral blood. Patients were considered to have complete hematological response if they had a decrease in marrow blasts to less than 5%, disappearance of blasts in the peripheral blood, an absolute neutrophil count of more than 1 × 10 9 /l and platelet count of more than 100 × 10 9 /l. Marrow response was defined with the same marrow criteria but no recovery of blood counts. Partial response was defined as a decrease of marrow blasts to 5-15%. [18] [19] [20] Restoration of hematological features consisting of a second chronic phase in patients with CML was also considered hematological response. Cytogenetic response was evaluated by standard interphases FISH and by using FISH with extra signal dual-color probes. 28 Standard band cytogenetic analysis is still the gold standard for assessment of responses yet it is less sensitive and cumbersome and therefore was not used routinely in this study. FISH has been shown in a comparative trial to be a reliable method 29 and in particular, when used with the extra signal probes is very accurate with very low false positive rates. 28 Therefore we used this method for assessment of cytogenetic response. However, we defined a cytogenetic response rather than complete cytogenetic response when there was complete disappearance of the BCR/ABL fusion in FISH analysis of marrow samples. Quantitative determination of major or partial cytogenetic responses was not used. Molecular response was not determined. Relapse was defined as hematological progression with increase of bone marrow blasts to more than 5% or more than 15% if only PR was achieved post transplant. Chimerism was tested by FISH with X and Y probes in sexmismatched transplants and with PCR analysis of short tandem repeats in sex-matched transplants. 30 Post-transplant parameters were recorded. Toxicity post transplantation was graded by the Bearman scale. 31 Neutrophil and platelet engraftment were defined as the first of 3 days with neutrophil count >0.5 × 10 9 /L and the first of 7 days with untransfused platelet count >20 × 10 9 /l, respectively. Acute and chronic GVHD were graded and staged by standard criteria.
Statistical analysis
Overall and disease-free survivals were calculated from the day of transplantation. Survival curves, relapse and GVHD rates and non-relapse mortality rates were estimated and plotted using the Kaplan-Meier method 32 and compared with the log-rank test.
Results
Sixteen patients were treated with imatinib for Philadelphiapositive acute leukemia either in preparation for allogeneic transplantation (n = 15) or as treatment of post-transplant relapse and prior to DLI (n = 4, three of them also received imatinib prior to transplantation). All patients ultimately received the planned transplant or DLI treatment with no relation to prior response to imatinib. The primary indication for imatinib before transplantation was treatment of active leukemia (n = 12) or maintenance treatment while searching for an unrelated donor (n = 2) or while treating fungal pneumonia pre-transplant (n = 1). In two patients with active leukemia imatinib was continued as maintenance until unrelated donor transplant became feasible. The patient characteristics are outlined in Table 1 . The median age was 44 years (range, 23-61), 10 men and six women. Seven patients had CML in myeloid-BC, nine patients had lymphoblastic leukemia either CML in lymphoid-BC (n = 3) or Ph + ALL (n = 6). At the time of first initiation of imatinib therapy, the patients were a median of 8 months from diagnosis (range, 4-120 months, 16 months for CML patients and 3 months for ALL patients). The donor was an HLA-matched sibling (n = 5), matched unrelated donor (n = 9) or one haplotype identical-related donor (n = 2).
Imatinib prior to allogeneic transplantation
Response:
Fifteen patients were given imatinib for a median of 30 days (range, 14-150 days) prior to allogeneic transplantation. The intent was to achieve significant cytoreduction, not necessarily maximal response (such as complete molecular response) and to proceed to transplantation as soon as response was achieved and a donor was available. Therefore three of the patients were given imatinib for 14 days only ( Table 1 ). Four of the seven patients with CML in myeloid BC had restoration of chronic phase (considered complete hematological response), two had partial response and one had no response. Overall response was 86% and complete hematological response rate was 57%. Five of eight patients with ALL/lymphoid BC were given imatinib for the treatment of active leukemia. Two (40%) had complete hematologic response, two had marrow responses (not determined complete due to thrombocytopenia only) and one had partial response. One of these patients relapsed on therapy 2 months later, while awaiting search for an unrelated donor. Three patients were given imatinib to maintain CR achieved by standard chemotherapy while waiting for an unrelated donor transplant (n = 2) or while treating fungal pneumonia prior to transplantation (n = 1). All maintained CR until transplant. Imatinib was generally well tolerated with a few patients sustaining bone pain, muscle cramps and fluid retention. None had to discontinue treatment due to intolerability or sideeffects.
Transplantation outcome:
Fourteen of 15 patients given imatinib prior to transplantation engrafted. The median time to ANC 0.5 × 10 9 /l was 14 days (range, 11-21 days). The median time to platelet 20 × 10 9 /l was 25 days (range, 13-32
293
SPOTLIGHT
days, four patients did not achieve platelet transfusion independency). One patient had primary graft failure but engrafted with infusion of additional stem cell from the same donor. Mucositis occurred in most patients. Liver toxicity as evidenced by elevation of bilirubin and/or transaminases was common. Three patients developed grade III toxicity and four grade II toxicity by the Bearman criteria. Two of these patients also had additional criteria such as hepatomegaly and/or fluid retention to define veno-occlusive disease (VOD). Grade III renal toxicity occurred in one patient and grade II cardiac, renal and bladder toxicity occurred in one patient each.
Seven patients (54% of the 13 recipients of non-T celldepleted grafts) had acute GVHD grade II-IV and four (31%) had grade III-IV. The estimated risk is 71 ± 13% and 39 ± 15% respectively. Five of 12 evaluable patients (42%) had chronic GVHD.
With a median follow-up of 10 months (range, 3-16), six patients are alive and nine have died. The median survival is 200 days, the estimated 1-year survival is 25 ± 11% ( Figure  1 ). The estimated 1-year disease-free survival is 10 ± 9%. The rates among the patients achieving complete hematologic response with pre-transplant imatinib are 35 ± 19% and 15 ± 13%, respectively. None of the non-responders to pre-transplant imatinib survived (P = 0.02). Four of eight patients with lymphoid-BC/ALL are alive, median survival 409 days, estimated OS 30% in comparison with two of seven patients with myeloid BC, median survival 129 days, estimated OS 19% (P = NS) (Figure 2 ). The median survival from diagnosis of BC was 410 days, the 1-year and 2-year survival was 54 Ϯ 13% and 23 Ϯ 13%, respectively. All patients initially achieved full chimerism as assessed by FISH for XY probes in sex-mismatched transplants and by PCR-STR in sex-matched transplants. FISH analysis showed complete disappearance of bcr/abl fusion in all patients. However, three patients relapsed post transplant (20%, projected risk 57%) (Figure 3) , all in the ALL/lymphoid BC group (P = 0.07). Two were successfully salvaged with reintroduction of imatinib and DLI (see below). Non-relapse mortality occurred in eight patients (three acute Figure 1 Kaplan-Meier estimates of overall survival after allogeneic transplantation for 15 patients with CML in blast crisis or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib prior to transplantation. The estimated 1-year survival is 25 ± 11%.
Leukemia
Figure 2
Kaplan-Meier survival estimates after allogeneic transplantation by disease phenotype. The median 1-year survival rates are 409 days and 30% in patients with lymphoid-BC/ALL vs 129 days and 19% in patients with myeloid BC, respectively (P = NS). Myeloid, CML in myeloid blast crisis; lymphoid, CML in lymphoid blast crisis or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Figure 3
Kaplan-Meier estimates for relapse after allogeneic transplantation. Three of 15 patients relapsed post transplant (20%). The projected risk is 57% within the first year after transplantation. All relapses were in the ALL/lymphoid BC group. GVHD, one chronic GVHD, three infections, one VOD). The 1-year estimated risk was 50% (62% in myeloid BC patients and 40% in lymphoid, P = NS) (Figure 4) . When excluding the two haplo-identical transplants (both patients died of nonrelapse causes) the estimated 1-year risk was 42%.
Imatinib prior to donor lymphocyte infusion
Four patients were given imatinib as treatment of recurrent leukemia post transplantation in preparation for DLI (Table 1 , patients 1, 2, 5, 11). Two had CML relapsing in lymphoid BC post transplant and two had relapsing Ph + ALL. Relapse occurred in a median of 7 months from transplantation (range,
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Figure 4
Kaplan-Meier estimates of non-relapse mortality after allogeneic transplantation. Non-relapse mortality occurred in eight patients (three acute GVHD, one chronic GVHD, three infections, one VOD). The 1-year estimated risk is 50%.
1.5-12 months)
. Three have been treated with imatinib prior to transplant but none post transplant. All four patients had complete hematologic response (Table 2) . FISH analysis showed complete disappearance of BCR/ABL fusion in all four patients. Overall response rate was 100%. The median time to response was 14 days (range, 13-28). DLI was given as one infusion of 1 × 10 8 CD3 + cells/kg from sibling (n = 3) or unrelated (n = 1) donor. Imatinib was continued in three patients and discontinued shortly after DLI in one patient due to post-DLI bone marrow aplasia. Acute GVHD occurred rapidly within 11-14 days after DLI in all four patients. Acute GVHD grade III-IV occurred in three patients and resulted in the death of one patient. One patient had acute GVHD grade II. One patient, who was not maintained on imatinib post DLI, relapsed 4 months post DLI and died. The remaining two are alive in complete remission 4.5 and 5 months post-DLI, respectively.
Discussion
Imatinib is a novel rationally designed molecule for the treatment of Philadelphia chromosome-positive leukemia. Data are emerging which better define its role in the treatment of the various phases of these diseases and in combination with transplantation strategies. In this study, we investigated a novel approach using short-term therapy with imatinib for remission induction or maintenance to be followed by allogeneic transplantation or DLI. This is the first series reported using this rationale. Not withstanding that the patient groups studied were heterogeneous and relatively small, certain observations made can direct future larger scale studies using this approach. This study was not designed to assess overall response to imatinib as patients were selected on the basis of transplant eligibility. However, 14 of 15 patients treated prior to transplant showed at least partial response confirming the substantial activity of imatinib in both types of BC as recently reported in large phase II studies. 18, 19, 21 Pre-transplant treatment with imatinib allowed us to transplant patients in a more favorable status. Eleven of 15 patients were transplanted in complete hematologic response or in a second chronic phase. Imatinib opened a window of opportunities for transplantation in a more favorable status. However, this window may only be of short duration, especially in lymphoid disorders where the median response duration is 2 months, 20 and indeed, one of our patients relapsed on therapy while waiting for donor availability and required additional chemotherapy. Overall, responses were achieved with little toxicity, allowing the patients transplantation in good performance status.
Imatinib had a significant role prior to transplants from an unrelated donor. Imatinib was used to maintain remission for short durations (up to 5 months) until the donor was available, without the toxicity associated with further chemotherapy. It SPOTLIGHT was also used when transplant was delayed due to temporary ineligibility to transplant, such as while treating fungal pneumonia. A larger patient group is required to better define this novel previously unreported indication for imatinib.
Results in our study group remained unsatisfactory and disappointing. The 1-year survival for the entire group was only 25%. For the 11 patients responding to imatinib the projected survival was 35% but DFS was only 15%, two patients being salvaged with further imatinib therapy and DLI. The study group may have been too small to detect the advantages of transplantation during chronic phase. Also, our study included mostly high-risk transplants with only four of the transplants that followed imatinib therapy being from matched siblings. Otherwise a second remission achieved after imatinib may not have the same prognostic implication as chemotherapyinduced remission, as also suggested by others. 6 There are as yet no data regarding the effect of pre-transplant imatinib on engraftment, toxicity, GVHD, and survival following transplant and how long before transplantation it should be discontinued. Similar discussion has been raised for the effect of pre-transplant therapy with interferon on transplant outcome, which is controversial and with conflicting results in different studies. [33] [34] [35] [36] In this study we have continued imatinib until the start of conditioning in most patients. The median duration of imatinib therapy was relatively short, 30 days (range, 14-150), since imatinib was only administered as preparation for transplantation. We have not noticed any substantial delay in engraftment or increased rate of nonengraftment. In contrast to other reports, treatment in second response was still associated with substantial toxicity. The estimated 1-year non-relapse mortality was 50%, mostly from GVHD and infections. Of particular concern was the relatively high incidence of hepatic toxicity, with three patients developing grade III and four patients grade II hepatic toxicity, and one death from VOD. Imatinib has hepatotoxic potential as evidenced by frequent elevation of transaminases or bilirubin occurring in one study in 14% of patients a median of 16 days (range 7-194) after initiation of therapy. 20 In another study of patients with myeloid BC 8% of patients treated with imatinib had grade III-IV hepatic toxicity and 47% grade I-II. 19 The occurrence of hepatic dysfunction was less than 1% in patients with CML in chronic phase 17 and was also limited in two other studies of patients in BC. 18, 21 However, our study group included very high-risk patients most also recipients of unrelated donor transplants and following intensive conditioning. Other studies have also observed high-risk of non-relapse mortality in these patients. In particular, Wadhwa et al 6 reported that seven of 23 recipients of allogeneic transplantation developed VOD. We cannot rule out that late discontinuation of imatinib within a few days of conditioning contributed to the high rate of hepatic toxicity. The timing of imatinib discontinuation needs to be defined in larger-scale studies. We have also noticed a relatively high rate of acute GVHD with an estimated risk of 39% and 71% for grade III-IV and grade II-IV, respectively. This rate can be expected considering the high-risk patient population treated, most of them recipients of unrelated donor transplantations. 37 The small patient number precludes analysis of GVHD localization but a larger study may detect changes in the patterns of GVHD following imatinib therapy. We have not observed excess complications in a group of five additional patients with chronic phase CML transplanted after failure of imatinib therapy (data not shown). Therefore, we cannot conclude that prior imatinib treatment was related to excess post-transplant toxicity or GVHD rates. However, a direct comparison in a Leukemia larger group of patients and in a more homogenous disease status is needed to confirm this observation.
There are few reports of the use of imatinib for treatment of post-transplant relapse, which has been occasionally successful after failure of prior DLI. [22] [23] [24] [25] [26] [27] Our novel policy combining imatinib and early DLI for the treatment of post-transplantation relapse yielded encouraging results. All four patients achieved complete hematologic response and also negative FISH tests. Two patients are alive and in complete response approximately 6 months post relapse. DLI is relatively ineffective when administered in patients with active leukemia who often continue to progress rapidly after DLI. Imatinib was effective in allowing a transient response until the generation of effective immune response after DLI. We have noticed high risk for severe GVHD after DLI most probably related to the large number of lymphocytes infused. By reducing leukemia bulk imatinib may not only increase the likelihood of controlling leukemia with DLI but may also allow the use of a lower dose of donor lymphocytes thus reducing the risk of GVHD and aplasia. None of the three patients maintained with imatinib post DLI relapsed although one died of GVHD. This suggests that imatinib may be effective in controlling minimal residual disease and thus imatinib may have a role as post-transplantation maintenance therapy in high-risk patients. Since allogeneic transplantation following our intensified conditioning was associated with high non-relapse death rate it may be feasible to decrease conditioning intensity and combine post-transplant imatinib therapy to control residual disease with the addition of donor lymphocytes as required.
In conclusion, treatment with imatinib allows transplantation in a more favorable status or maintaining remission for short durations with low toxicity until transplantation is feasible. Pre-transplant imatinib seems safe. Imatinib may have substantial activity in combination with DLI. Further study of a larger group of patients is required to assess the impact on long-term outcome and the role of post-transplant imatinib in controlling residual disease.
